Treatment of Chronic Delta Hepatitis With Lonafarnib and Ritonavir

Trial Profile

Treatment of Chronic Delta Hepatitis With Lonafarnib and Ritonavir

Completed
Phase of Trial: Phase II

Latest Information Update: 23 Apr 2017

At a glance

  • Drugs Lonafarnib (Primary) ; Ritonavir
  • Indications Hepatitis D
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms LOWR HDV - 3
  • Most Recent Events

    • 21 Apr 2017 According to an Eiger BioPharmaceuticals, Inc. media release, data from the study has been presented at the The International Liver Congress 2017.
    • 21 Apr 2017 Results from the LOWER HDV program published in an Eiger BioPharmaceuticals, Inc. media release.
    • 06 Apr 2017 Status changed from active, no longer recruiting to completed, according to a Eiger BioPharmaceuticals, Inc. media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top